Millennium Retains Velcade U.S. Rights; J&J Picks Up Half Of R&D Costs

Millennium's Velcade agreement with Johnson & Johnson allows the biotech company to retain rights to the oncologic in the U.S., while requiring J&J to pick up nearly half of future worldwide development costs